Quizartinib -Daiichi Sankyo Company

Drug Profile

Quizartinib -Daiichi Sankyo Company

Alternative Names: AC-010220; AC-220; ASP-2689

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ambit Biosciences Corporation
  • Developer Cancer Research UK; Cardiff University; Daiichi Sankyo Company; University of Texas M. D. Anderson Cancer Center
  • Class 3-ring heterocyclic compounds; Antineoplastics; Benzothiazoles; Imidazoles; Isoxazoles; Morpholines; Phenylurea compounds; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II/III Myelodysplastic syndromes
  • No development reported Acute lymphoblastic leukaemia; Solid tumours

Most Recent Events

  • 15 Sep 2017 MD Anderson Cancer Center and Daiichi Sankyo plans phase I and phase II trials for Acute myeloid leukemia
  • 15 Sep 2017 MD Anderson Cancer Center and Daiichi Sankyo agree to co-develop Quizartinib for Acute myeloid leukemia
  • 22 Jun 2017 Pharmacokinetic and adverse events data from a phase I trial presented at the 22nd Congress of the European Haematology Association (EHA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top